FEDERAL COURT OF AUSTRALIA
AFT Pharmaceuticals (AU) Pty Ltd v Reckitt Benckiser (Australia) Pty Ltd [2020] FCA 672
File number: NSD 252 of 2019 Judge: GLEESON J Date of judgment: 21 May 2020 Catchwords: CONSUMER LAW – applicant seeking declaration that there is adequate scientific foundation for certain statements in advertisement for analgesic drug – where applicant previously contravened the Australian Consumer Law (Sch 2 to the Competition and Consumer Act 2010 (Cth)) and is permanently restrained from making certain representations – whether proceeding barred by doctrine of res judicata or subject to issue estoppel – whether new advertising materials convey restrained representation – whether adequate scientific foundation for new statements of superiority over certain other analgesics – application refused.
CONSUMER LAW – cross-claim – whether cross-respondent’s new advertisements for analgesic drug contravenes Australian Consumer Law – misleading or deceptive conduct – false or misleading representations – whether adequate scientific foundation for representation as to superiority of applicant’s analgesic over certain other analgesics – contraventions found
Legislation: Australian Consumer Law (Sch 2 to the Competition and Consumer Act 2010 (Cth)) ss 18, 29, 33 Cases cited: Australian Competition and Consumer Commission v Coles Supermarkets Australia Pty Ltd [2014] FCA 634
Australian Competition and Consumer Commission v Harris Scarfe Australia Pty Ltd [2009] FCA 54
Australian Competition and Consumer Commission v Signature Security Group Pty Ltd [2003] FCA 3
Australian Competition and Consumer Commission v TPG Internet Pty Ltd [2013] HCA 54; (2013) 250 CLR 640
AFT Pharmaceuticals (AU) Pty Limited v Reckitt Benckiser (Australia) Pty Limited [2020] FCAFC 45
Blair v Curran [1939] HCA 23; (1939) 62 CLR 464
iNova Pharmaceuticals (Australia) Pty Ltd v Reckitt Benckiser (Australia) Pty Ltd [2018] FCA 1209
Jackson v Goldsmith [1950] HCA 22; (1950) 81 CLR 446
Medical Benefits Fund of Australia Ltd v Cassidy [2003] FCAFC 289; (2003) 135 FCR 1
National Exchange Pty Ltd v Australian Securities and Investments Commission [2004] FCAFC 90
Re Twenty-First Larena Pty Ltd; Maximova v Goodwin & Ors [2010] VSC 84
Reckitt Benckiser (Australia) Pty Limited v AFT Pharmaceuticals (AU) Pty Limited [2018] FCA 1552
Reckitt Benckiser (Australia) Pty Ltd v GlaxoSmithKline Australia Pty Ltd [2018] FCAFC 138
Tobacco Institute of Australia Ltd v Australian Federation of Consumer Organisations Inc [1992] FCA 630; (1992) 38 FCR 1
Tomlinson v Ramsey Food Processing Pty Ltd [2015] HCA 28; (2015) 256 CLR 507
Trade Practices Commission v QDSV Holdings Pty Ltd (t/as Bush Friends Australia) [1994] FCA 1562
Trawl Industries of Australia Pty Ltd v Effem Food Pty Ltd [1992] FCA 272
Date of hearing: 23-25 July 2019 Date of last submissions: 6 August 2019 Registry: New South Wales Division: General Division National Practice Area: Commercial and Corporations Sub-area: Regulator and Consumer Protection Category: Catchwords Number of paragraphs: 202 Counsel for the Applicant/Cross-Respondent: P Crutchfield QC and L Merrick Solicitor for the Applicant/Cross-Respondent: Corrs Chambers Westgarth Counsel for the Respondent/Cross-Claimant: N Murray SC with A Vincent and J Edwards Solicitor for the Respondent/Cross-Claimant:
Keep reading for free
Create a free CaseChat account to read AFT Pharmaceuticals (AU) Pty Ltd v Reckitt Benckiser (Austra... and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2020] FCA 672
- Decision Date
CaseChat Overview and Summary
The primary legal issue was whether there was an adequate scientific foundation for the claims made in the new advertisement, and whether the new advertising materials conveyed the restrained representation. This required an analysis of the scientific evidence provided by both parties and the interpretation of the relevant legal standards.
The Court found that the new advertisement and training aid did not convey a representation that Maxigesic provided faster onset and more meaningful pain relief than paracetamol and ibuprofen alone. The Court also found that the new advertising materials contravened the Australian Consumer Law as they conveyed the restrained representation and lacked an adequate scientific foundation. The Court considered the evidence provided by both parties and concluded that the new advertising materials did not have an adequate scientific foundation.
The Court refused the declaration sought by AFT Pharmaceuticals (AU) Pty Ltd and found that the new advertising materials contravened the Australian Consumer Law. The Court ordered that on or before 26 May 2020, the parties file and serve submissions in support of any application for non-publication of information contained in the reasons for judgment. Additionally, the parties were required to file and serve short minutes of orders to give effect to these reasons on or before 4 June 2020.
Orders
Orders of the court
1. On or before 26 May 2020, the parties file and serve submissions in support of any application for non-publication of information contained in the reasons for judgment.
2. On or before 4 June 2020, the parties file and serve short minutes of orders to give effect to these reasons.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi